Cargando…
Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
Background: In the last years, inflammatory bowel disease (IBD) and hepatitis C virus (HCV) infection management has completely changed. However, the role of direct-acting antivirals (DAAs) and the correct timing of antiviral drugs administration in IBD patients needing biologics has not been evalua...
Autores principales: | Imperatore, Nicola, Castiglione, Fabiana, Rispo, Antonio, Sessa, Anna, Caporaso, Nicola, Morisco, Filomena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702483/ https://www.ncbi.nlm.nih.gov/pubmed/29209223 http://dx.doi.org/10.3389/fphar.2017.00867 |
Ejemplares similares
-
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018) -
PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease
por: Tortora, Raffaella, et al.
Publicado: (2018) -
Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
por: Mushtaq, Saima, et al.
Publicado: (2022) -
Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents
por: Cossiga, Valentina, et al.
Publicado: (2022) -
Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis
por: Rispo, Antonio, et al.
Publicado: (2016)